Tetratherix Limited (ASX: TTX)
Health Care · Biotechnology · AU
AU$6.67
-11.30% today · +49.2% 1Y
Tetratherix Limited (ASX: TTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $250.87M and employs 15 people.
Over the last twelve months the share price has gained 49.2%, trading between 3.09 and 8.08.
Tweenvest scores Tetratherix Limited across four factors: quality 27/100, value 61/100. Its strongest factor is value.
TTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $250.87M
- Revenue (TTM)
- $1.33M
- P/E
- —
- EPS
- -0.31
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- AU$8.08
- 52-week low
- AU$3.09
- Avg volume (3M)
- —
- Shares outstanding
- 53.06M
- Employees
- 15
- Next earnings
- —
About Tetratherix Limited
Established in 2015 and headquartered in Alexandria, Australia, Tetratherix Ltd. operates in the biomaterials and regenerative medicine sectors across both domestic and international markets. The company develops and supplies products using its proprietary Tetramatrix platform technology, with a focus on applications including bone regeneration, tissue spacing, and advanced tissue healing.
- ISIN
- AU0000400574
- Founded
- 2015
- Listed since
- Jun 30, 2025
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.